摘要
目的:观察阿昔莫司联合复方甘草酸苷治疗非酒精性脂肪性肝炎(NASH)的临床疗效。方法:选取2021年1月—10月我院收治的NASH患者45例作为研究对象,均给予阿昔莫司联合复方甘草酸苷治疗,分析治疗总有效率及治疗前后肝功能及血脂水平、肝脏脂肪度值(CAP值)的变化。结果:治疗4周后,45例患者显效6例、有效36例、无效3例,总有效率为93.33%;治疗4周后患者ALT、AST、TG、TC水平及肝脏脂肪度低于治疗前(P<0.05)。结论:阿昔莫司联合复方甘草酸苷治疗NASH患者疗效显著,可明显改善患者的肝功能,降低血脂水平,降低肝脏脂肪度。
Objective: To observe the clinical efficacy of acipimox combined with compound glycyrrhizin in the treatment of nonalcoholic steatohepatitis(NASH). Methods: A total of 45 patients with NASH admitted to our hospital from January to October 2021 were selected as the research objects. All patients were treated with acipimox combined with compound glycyrrhizin. The total effective rate of treatment and the changes of liver function, blood lipid level and liver fat degree(CAP value) before and after treatment were analyzed. Results: After 4 weeks of treatment, 6 cases of 45 patients were significantly effective, 36 cases were effective, 3 cases were ineffective, and the total effective rate was 93.33%. After 4 weeks of treatment, the levels of ALT, AST, TG, TC and liver adiposity were lower than those before treatment(P<0.05).Conclusion: Acipimox combined with Compound Glycyrrhizin has a significant effect in the treatment of NASH patients,which can significantly improve the liver function, reduce the level of blood lipid and liver adiposity value.
作者
王燕平
梁海军
杨道坤
WANG Yanping;LIANG Haijun;YANG Daokun(Department of Infection,the First Afiliated Hospital of Xinxiang Medical College,Xinxiang 453100,Henan,China)
出处
《中国药物滥用防治杂志》
CAS
2022年第12期1805-1807,共3页
Chinese Journal of Drug Abuse Prevention and Treatment
基金
河南省医学科技攻关计划联合共建项目(编号:LHGJ20210532)。
